Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Parecoxib Ad Cited By U.K. For Using Out-Of-Date Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

A journal ad for parecoxib, marketed as Dynastat in the U.K., did not mention two warnings recently added to the COX-2 inhibitor for use in congestive heart failure and coronary artery bypass graft patients. The Medicines & Healthcare Products Regulatory Agency is requesting a corrective statement. The parecoxib NDA is pending at FDA.

You may also be interested in...



Merck Withdraws Fosamax UK Ad Claiming Superiority To Generic

UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.

Merck Withdraws Fosamax UK Ad Claiming Superiority To Generic

UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.

Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk

FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel